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Histone deactylase inhibitors (HDACi) are common chemotherapeutic agents that stimulate
Epstein–Barr virus (EBV) reactivation; the detailed mechanism remains obscure. In this study, it is
demonstrated that PKCd is required for induction of the EBV lytic cycle by HDACi. Inhibition
of PKCd abrogates HDACi-mediated transcriptional activation of the Zta promoter and
downstream lytic gene expression. Nuclear translocation of PKCd is observed following HDACi
stimulation and its overexpression leads to progression of the EBV lytic cycle. Our study suggests
that PKCd is a crucial mediator of EBV reactivation and provides a novel insight to study the
regulation of the EBV lytic cycle.
Epstein–Barr virus (EBV) is a human gammaherpesvirus
with both latent and lytic states in its life cycle (Kieff &
Rickinson, 2001). EBV reactivation not only produces
infectious viral progeny, but also contributes to the
development of EBV-related disease (Kieff & Rickinson,
2001). Although the majority of EBV infections in vivo are
latent, serological studies suggest that EBV reactivation
may occur months or years before the clinical diagnosis of
nasopharyngeal carcinoma (NPC), Hodgkin’s disease and
endemic Burkitt’s lymphoma, serving as a risk factor for
cancer development (Kieff & Rickinson, 2001). Previous
studies have shown that some physiological stimuli and
pharmacological agents, including transforming growth
factor beta, cross-linking of surface immunoglobulin,
phorbol ester, histone deacetylase inhibitors (HDACi)
and several genotoxic agents, can induce EBV from latent
status into the lytic cycle (Daibata et al., 1994; Davies et al.,
1991; Feng & Kenney, 2006; Feng et al., 2002; Schuster et al.,
1991).
The protein kinase C (PKC) family has been known for a
long time to be necessary for EBV reactivation following
stimulation with 12-O-tetradecanoyl phorbol 13-acetate
(TPA) (Davies et al., 1991) or anti-immunoglobulin
treatment (Daibata et al., 1994). The PKC family comprises
11 isozymes, which are classified into three subfamilies
according to their structure and regulatory domains
activated by calcium or diacylglycerol (DAG) (Newton,
1997). Conventional PKCs (PKCa, bI, bII and c) require
calcium and DAG activators, and novel PKCs (PKCd, e, h
and g) respond only to DAG and not to calcium (Newton,
1997). However, atypical PKC isoforms (PKCf, i/l and m)
are DAG-insensitive (Newton, 1997). Until now, it has not
been clear which PKC members are involved in EBV
reactivation. The limited information available suggests
that PKCs may play an important role during different
stages of various virus infections (Constantinescu et al.,
1991; Sieczkarski et al., 2003). For example, PKCf or PKCd
is required for early infection or TPA-triggered lytic-cycle
activation of Kaposi’s sarcoma-associated herpesvirus
(KSHV) (Deutsch et al., 2004; Naranatt et al., 2003).
HDACi, including trichostatin A (TSA), sodium butyrate
(SB) and valproic acid, are common agents used to induce
the EBV lytic cycle in several EBV-harbouring epithelial
and B cells (Chang & Liu, 2000; Luka et al., 1979). By
inactivating cellular HDAC enzyme activity, HDACi can
prevent histone acetyltransferase (HAT) recruitment from
reducing histone hyperacetylation and chromatin access-
ibility, thereby facilitating transcriptional activation of
their targeted genes (Marks & Dokmanovic, 2005). The
molecular mechanisms by which HDACi regulate expres-
sion of their target genes remain unclear; however, some
protein kinases have been reported to be required for
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HDACi-regulated gene expression, including phosphatidy-
linositol 3-kinase (PI3K), ATM and PKCs (Eun et al., 2007;
Ju & Muller, 2003; Kim et al., 2003, 2007). Recent studies
have shown that PKCe or PKCd is involved in HDACi-
mediated p21 or cyclin D3 gene expression (Kim et al.,
2003, 2007). Considering that EBV belongs to the
gammaherpesviruses and its lytic cycle in response to
HDACi is well-defined, it is interesting to investigate which
PKC isoform is required for HDACi-induced EBV
reactivation.
TPA and HDACi have been reported to induce progression
of the EBV lytic cycle (Chang & Liu, 2000; Davies et al.,
1991). The effects of TPA or HDACi can be mediated
through several pathways; however, PKC is a common
signal transducer for both (Davies et al., 1991; Kim et al.,
2007). To determine which PKC isoform is involved in
HDACi-induced EBV reactivation, Go¨6850 (PKCa/bI/bII/
c/e/d inhibitor), Go¨6976 (PKCa/b/m inhibitor) and
Rottlerin (PKCd inhibitor) were used in this study.
As shown in Fig. 1(a), TSA induced immediate-early
(a) (b)
(c) (d)
(e) (f)
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lytic-cycle protein expression in an Akata EBV-infected
NPC cell line (NA), including Zta, Rta and EA-D proteins
(Chang et al., 2004b). However, the TSA-induced EBV lytic
protein expression could be suppressed by Go¨6850 (lane 4)
and Rottlerin (lane 6), but not by Go¨6976 (lane 8).
Furthermore, TSA- or SB-mediated EBV reactivation also
could be suppressed by Rottlerin treatment of another
Akata EBV-infected NPC cell line, HA (Fig. 1b) (Chang
et al., 2004b). These results demonstrated that PKCd is the
key mediator of TSA- and SB-induced EBV lytic-cycle
progression in the EBV-positive NA and HA cell lines.
To confirm the specificity of the inhibitors and the role of
PKCd in HDACi-induced EBV reactivation, the expression
of PKCd was knocked down specifically by PKCd-targeted
small interfering RNA (siPKCd) (Storz et al., 2004). As
shown in Fig. 1(c), EBV lytic-cycle protein expression can
be induced by SB treatment in vector-control NA cells
positive for green fluorescent protein-targeted siRNA
(siGFP); however, the expression of SB-induced EBV
lytic-cycle proteins was inhibited almost completely in
the presence of siPKCd. To elucidate the working
mechanisms of PKCd, a deletion mutant of the catalytic
domain (from aa 299 to 654) of PKCd (EGFP-CD-PKCd)
was constructed. The expression of SB-induced EBV lytic
proteins was compared in enhanced green fluorescent
protein (EGFP)- and EGFP-CD-PKCd-transfected HA
cells. In Fig. 1(d), SB-stimulated EBV reactivation was
clearly downregulated in the presence of the PKCd
dominant-negative mutant, suggesting that CD-PKCd
could also block endogenous PKCd activities that are
required for the SB-induced EBV lytic cycle. This result
also implies that HDACi may induce PKCd activation to
trigger EBV reactivation.
The activation of PKCd can be measured by detecting
several markers, including translocation to other subcel-
lular compartments, phosphorylation at particular sites
and cleavage into catalytic fragments (Shirai & Saito, 2002;
Steinberg, 2004; Yamamoto et al., 2006). Because PKCd has
a nuclear-localization sequence (Steinberg, 2004), we
examined whether PKCd translocated to the nucleus,
which is the main site of PKCd activation. In the absence
of TSA, PKCd was expressed mostly in the cytosol, but was
also expressed at low levels in the nucleus (Fig. 1e, upper
panel). However, PKCd translocated predominantly to the
nucleus 8 h after TSA treatment (Fig. 1e, bottom panel).
We also found that enhancement of phosphorylation at
threonine 505 (p-Thr-505) and the cleaved form of PKCd
were observed after TSA treatment (Fig. 1f). Taken
together, we believe that TSA can induce PKCd activation,
which is necessary for the subsequent reactivation of EBV.
BZLF1 gene expression governs the initiation of EBV
reactivation. To determine whether PKCd affected TSA-
induced BZLF1 gene expression, we investigated the
expression of BZLF1 mRNA in the presence of Rottlerin
in TSA-treated NA cells. Fig. 2(a) shows that TSA-induced
BZLF1 gene expression was blocked by Rottlerin. To
confirm whether PKCd regulated TSA induction of BZLF1
gene expression, the promoter activity of Zp was measured
in NA cells treated with Rottlerin. As shown in Fig. 2(b, c),
Rottlerin suppressed TSA- and SB-induced Zp activity in
NA cells (decreasing Zp activity from 5-fold to 1-fold and
from 30-fold to 10-fold, respectively). Previous studies
have reported that TSA stimulation usually increases
expression of acetyl-histone H3 and H4 proteins, which
then facilitates transcriptional activation of certain genes
(Marks & Dokmanovic, 2005). We attempted to determine
Fig. 1. (on previous page) PKCd is required for TSA- or SB-induced EBV lytic-cycle progression. (a) Inhibition of TSA-triggered
EBV lytic cycle by PKC inhibitors. NA cells were treated with PKC inhibitors [10 mM Go¨6850, 5 mM Rottlerin or 0.4 mM Go¨6976
(Calbiochem)] or with DMSO (solvent control). After 1 h, cells were treated with 1.25 mM TSA (+) or mock-treated (”) for 24 h.
Proteins were detected by anti-Zta, anti-Rta, anti-EA-D and anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
antibodies (Santa Cruz Biotechnology). (b) Suppression of TSA-triggered EBV lytic cycle by PKCd inhibitor. HA cells were treated
with Rottlerin for 1 h, and then treated with 1.25 mM TSA or 3 mM SB (+) or mock-treated (”) for 24 or 48 h. Western blotting
was performed to detect protein expression as indicated. (c) Blockage of TSA-triggered EBV reactivation by PKCd siRNA.
pSUPER-derived GFP (siGFP) and PKCd (siPKCd) siRNA-expressing plasmids were constructed as described previously
(Chang et al., 2004a; Storz et al., 2004). NA cells were transfected once with siRNA expression plasmids and these transfected
cells were reseeded every 2 days. After three rounds of transfection, cells were treated with SB (+) or mock-treated (”) for 48 h
and then harvested for immunoblotting. (d) Repression of SB-induced EBV reactivation via overexpression of PKCd dominant-
negative mutants. NA cells were transfected with the EGFP-derived catalytic domain-deleted mutant of PKCd (plasmid EGFP-
CD-PKCd) or its vector control (EGFP-GFP) by using Lipofectamine 2000 reagent (Invitrogen) for 24 h, followed by treatment
with SB (+) or mock treatment (”) for another 48 h. Endogenous expression of PKCd and EGFP-CD-PKCd was examined by
using an anti-PKCd antibody (Santa Cruz Biotechnology). (e) TSA-induced PKCd nuclear translocation. NA cells grown on glass
slides were treated with TSA or mock-treated for 8 h and then subjected to an immunofluorescence assay as described previously
(Chua et al., 2007). Briefly, cells were washed with PBS and fixed with acetone at ”20 6C for 10 min and then incubated with anti-
PKCd antibody at 37 6C for 1 h. Cells were washed with PBS three times and then incubated with rhodamine-conjugated anti-
rabbit IgG at 37 6C for 1 h, followed by another three washes with PBS. Nuclei of cells were stained with Hoechst. (f) TSA-
induced PKCd catalytic-domain cleavage and Thr-505 phosphorylation. NA cells were treated with or without TSA for 0, 4, 12 or
24 h. Cell lysates were prepared for Western blot analysis using specific antibodies against PKCd (Santa Cruz Biotechnology)
and its phosphorylation site at Thr-505 (Cell Signaling Technology). Zta expression was examined for indication of the occurrence
of EBV reactivation, and b-actin was detected as an internal control.
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whether PKCd is involved in the regulation of HDACi-
induced acetyl-histone H3 and H4 protein expression, and
then regulates BZLF1 gene expression further. In Fig. 2(d),
it is shown that Rottlerin could not block TSA- or SB-
induced acetyl-histone H3 and H4 protein expression in
NA cells. To demonstrate that PKCd did not alter the
level of Zp-bound acetyl-histone H3 and H4 directly, a
chromatin immunopreciptation (ChIP) assay was per-
formed. We found no significant alteration of the level of
acetyl-histone H3 and H4 proteins on Zp after Rottlerin
treatment (Fig. 2e). Thus, PKCd-mediated HDACi-
induced BZLF1 gene expression is very unlikely to occur
though alteration of the expression or binding of acetyl-
histone H3 and H4 proteins on Zp.
We next questioned whether PKCd alone is sufficient
to induce Zp activation. In Fig. 3(a), overexpression of
wild-type PKCd could induce the activity of Zp by 5-fold
without HDACi treatment. Because the N-terminal
domain of PKC harbours a pseudosubstrate domain to
repress its C-terminal catalytic activity (House & Kemp,
1987), it has been suggested that N-terminal deletion of
PKCd leads to its constitutive activation (Emoto et al.,
1995). Overexpression of the catalytic fragment of PKCd
(CF-PKCd) could induce the activity of Zp by a further 9-
fold. In contrast, expression of CD-PKCd, with the catalytic
domain of PKCd deleted, could not induce the activity of
Zp. This result implied that activation of PKCd is necessary
to upregulate Zp activity. Next, we addressed whether
PKCd alone can induce EBV lytic-cycle progression. In
Fig. 3(b), overexpression of wild-type PKCd and CF-PKCd
could induce Zta and EA-D expression without HDACi
stimulation. In contrast, the CD-PKCd mutant could not
activate EBV lytic-cycle progression. It seemed that only
Fig. 2. Inhibition of PKCd represses TSA-induced BZLF1 mRNA expression, but does not alter TSA-induced histone
acetylation of Zp. (a) Expression of BZLF1 and GAPDH transcripts. NA cells were pre-treated with DMSO (”) or Rottlerin (+)
for 1 h, followed by treatment with TSA (+) or mock treatment (”) for 24 h. Total RNA was extracted by TRIzol reagent
(Invitrogen); mRNA expression of BZLF1 and GAPDH was analysed by RT-PCR in the presence (+) or absence (”) of reverse
transcriptase (RT). PCR conditions and primers were as described previously (Chua et al., 2007). (b, c) Zta promoter activities
are inhibited by Rottlerin. EBV-negative NPC-TW01 cells were transfected with pGL2-basic vector (Promega) or PGL2-
derived Zp reporter plasmid (pGL2-Zp-221, from ”221 to+12 bp) and EGFP expression plasmid (EGFP-C1, Promega) as an
internal control. After 24 h, the transfectants were pre-treated with DMSO (”) or Rottlerin (+) for 1 h, and then stimulated with
TSA (+, b) or SB (+, c) or mock-stimulated (”) for another 24 or 48 h. Cell lysates were harvested and subjected to a
luciferase gene reporter assay as described previously (Chang et al., 2006). (d) Effect of PKCd inhibition on global acetylation
of histone H3 and H4 proteins. NA cells were pre-treated with DMSO (”) or Rottlerin (+) for 1 h and then treated with TSA or
SB (+) or mock-treated (”) for 24 or 48 h. The expression of acetyl-histone H3 and H4 protein was detected by specific
antibodies (Cell Signaling Technology). (e) ChIP assay to detect Zp-bound acetyl-histone H3 and H4. NA cells were pre-
treated with (+) or without (”) Rottlerin for 1 h, followed by incubation with (+) or without (”) TSA for 24 h. ChIP assays were
performed according to the manufacturer’s protocol (Upstate Biotechnology). DNA was extracted with phenol/chloroform and
precipitated with ethanol, followed by PCR analysis with Zp primers. ‘Input’ indicates DNA input control, as assessed by b-
actin-targeted PCR analysis. PCR conditions and primers used are as described previously (Chua et al., 2007).
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CF-PKCd expression could induce expression of Zta and
EA-D sufficiently. This was consistent with the result that
overexpression of CF-PKCd enhanced the activity of Zp.
Thus, these results demonstrated that activation of PKCd is
sufficient to induce EBV reactivation.
Although preferentially remaining latent within host cells,
EBV has evolved some intricate mechanisms to reactivate
the lytic cycle and generate viral progeny (Kieff &
Rickinson, 2001). As immediate-early gene expression is
the first step in initiating EBV lytic reactivation, it is
plausible that immediate-early promoters must be tightly
controlled to ensure successful viral reactivation. In this
study, we demonstrate that PKCd is a crucial kinase for
EBV reactivation. Activation of PKCd is sufficient to
induce BZLF1 gene expression, whilst its inhibition can
prevent the HDACi-triggered EBV lytic cycle. Considering
that PKCd can be activated by DNA damage or HDACi, it
is worthwhile to investigate the regulation of PKCd and its
responsive effectors on immediate-early promoters in
governing human gammaherpesvirus reactivation. It also
raises the possibility that PKCd may recruit particular
transcription factors directly or indirectly to Zp for
subsequent transcriptional activation. Several reports have
indicated that an Sp1/Sp3-binding element is required for
HDACi-stimulated gene expression (Choi et al., 2002;
Davie, 2003; Kim et al., 2006, 2007; Yokota et al., 2004),
including KSHV ORF50 expression (Ye et al., 2005). Sp1/
Sp3-binding sites (ZIA, ZIC and ZID domains) are
responsive elements critical for TPA-induced Zp activation
(Kieff & Rickinson, 2001). It is worthwhile to investigate
whether Sp1/Sp3 is required for HDACi-initiated Zp
activation and to define further the roles of these
transcriptional factors in PKCd-mediated Zp activation.
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